Yonsei Med J.  2016 Sep;57(5):1209-1213. 10.3349/ymj.2016.57.5.1209.

The Efficacy of Low Molecular Weight Heparin for the Prevention of Venous Thromboembolism after Hip Fracture Surgery in Korean Patients

• Kim KK
• Won Y
• Won YY

• KMID: 2374167
• DOI: http://doi.org/10.3349/ymj.2016.57.5.1209

Abstract

PURPOSE
The aim of this study was to investigate the efficacy of low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in Korean patients who underwent hip fracture surgery (HFS).
MATERIALS AND METHODS
Prospectively, a total 181 cases were classified into the LMWH user group (116 cases) and LMWH non-user group (65 cases). Each group was sub-classified according to fracture types as follows: 81 cases of intertrochanteric fracture (group A: 49, group B: 32) and 100 cases of neck fracture (group C: 67, group D: 33). We compared the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) according to LMWH use.
RESULTS
Of the 181 cases, four DVTs were found in the LMWH user groups (1 in group A, and 3 in group C). One case of PE was found in LMWH non-user group D. The incidences of DVT and PE showed no statistically significant differences between the LMWH user and non-user groups (p=0.298 and 0.359, respectively). In subgroup analysis, no statistically significant differences were found between groups A and B and between groups C and D.
CONCLUSION
The administration of LMWH was not effective in the prevention of venous thromboembolism and PE in the Korean patients who underwent HFS.

Keyword

Low molecular weight heparin; deep vein thrombosis; pulmonary embolism; hip fracture

MeSH Terms

Aged
Anticoagulants/*therapeutic use
Female
Heparin, Low-Molecular-Weight/*therapeutic use
Hip Fractures/classification/*surgery
Humans
Male
Middle Aged
Postoperative Complications/*prevention & control
Pulmonary Embolism/etiology/*prevention & control
Republic of Korea
Venous Thromboembolism/*prevention & control
Venous Thrombosis/etiology/*prevention & control
Anticoagulants
Heparin, Low-Molecular-Weight

Figure

• 

  Fig. 1 Flowchart and proportion of patients with surgery type and LMWH use confirmed deep vein thrombosis. *Deep vein thrombosis, †Pulmonary thromboembolism. LMWH, low molecular weight heparin.

Reference

1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133:6 Suppl. 381S–453S.

2. Zahn HR, Skinner JA, Porteous MJ. The preoperative prevalence of deep vein thrombosis in patients with femoral neck fractures and delayed operation. Injury. 1999; 30:605–607.

3. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:2 Suppl. e278S–e325S.

4. Ji HM, Lee YK, Ha YC, Kim KC, Koo KH. Little impact of antiplatelet agents on venous thromboembolism after hip fracture surgery. J Korean Med Sci. 2011; 26:1625–1629.

5. Cha SI, Lee SY, Kim CH, Park JY, Jung TH, Yi JH, et al. Venous thromboembolism in Korean patients undergoing major orthopedic surgery: a prospective observational study using computed tomographic (CT) pulmonary angiography and indirect CT venography. J Korean Med Sci. 2010; 25:28–34.

6. Lee SY, Ro DH, Chung CY, Lee KM, Kwon SS, Sung KH, et al. Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. Yonsei Med J. 2015; 56:139–145.

7. Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J. 1987; 114:1262–1264.

8. Baker LW, Prajapat DK. Deep vein thrombosis in African and Indian patients. S Afr J Surg. 1974; 12:127–131.

9. Cunningham IG, Yong NK. The incidence of postoperative deep vein thrombosis in Malaysia. Br J Surg. 1974; 61:482–483.

10. Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994; 154:861–866.

11. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993; 90:1004–1008.

12. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996; 88:3698–3703.

13. Heijboer H, Brandjes DP, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990; 323:1512–1516.

14. Kim YH, Kim JS. The 2007 John Charnley Award. Factors leading to low prevalence of DVT and pulmonary embolism after THA: analysis of genetic and prothrombotic factors. Clin Orthop Relat Res. 2007; 465:33–39.

15. Lee KH, Kim JY, Yim SJ, Moon DH, Choi GH, Moon KH. Incidence and risk factors of subsequent hip fractures in Korea: multicenter study. J Korean Med Sci. 2014; 29:992–994.

16. Compston JE, Flahive J, Hosmer DW, Watts NB, Siris ES, Silverman S, et al. Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res. 2014; 29:487–493.

17. Schiff RL, Kahn SR, Shrier I, Strulovitch C, Hammouda W, Cohen E, et al. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis. Chest. 2005; 128:3364–3371.

18. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999; 82:610–619.

19. Smith EB, Parvizi J, Purtill JJ. Delayed surgery for patients with femur and hip fractures-risk of deep venous thrombosis. J Trauma. 2011; 70:E113–E116.

20. Sharnoff JG, DeBlasio G. Prevention of fatal postoperative thromboembolism by heparin prophylaxis. Lancet. 1970; 2:1006–1007.

21. Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med. 1995; 155:366–372.

22. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001; 161:1952–1960.

23. Kearon C. Natural history of venous thromboembolism. Circulation. 2003; 107:23 Suppl 1. I22–I30.

24. Schwartz T, Hingorani A, Ascher E, Marks N, Shiferson A, Jung D, et al. Pulmonary embolism without deep venous thrombosis. Ann Vasc Surg. 2012; 26:973–976.

25. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand. 2000; 71:47–50.